Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9P1F

Myoglobin variant RR22 in complex with imidazole

Summary for 9P1F
Entry DOI10.2210/pdb9p1f/pdb
DescriptorMyoglobin, IMIDAZOLE, SULFATE ION, ... (5 entities in total)
Functional Keywordsmetalloprotein, myoglobin, heme, oxygen storage
Biological sourcePhyseter macrocephalus (sperm whale)
Total number of polymer chains1
Total formula weight18575.06
Authors
Dayananda, T.,Jenkins, J.L.,Fasan, R. (deposition date: 2025-06-09, release date: 2026-02-04, Last modification date: 2026-02-11)
Primary citationShen, Z.,Siriboe, M.G.,Ren, X.,Dayananda, T.,Jenkins, J.L.,Khare, S.D.,Fasan, R.
Computational design of generalist cyclopropanases with stereodivergent selectivity.
Nat Commun, 2026
Cited by
PubMed Abstract: Stereodivergent catalysis, whereby the full complement of stereoisomeric products is obtained through a set of stereocomplementary catalysts, represents a powerful tool for synthetic organic and medicinal chemistry. Despite recent progress in engineering biocatalysts for new-to-nature cyclopropanation reactions, cyclopropanases featuring a combination of stereodivergent selectivity with broad substrate scope have been elusive. Here, we report a mechanism-based, multi-state computational design workflow useful for the design of 'generalist' cyclopropanation biocatalysts with tailored selectivity. Using this strategy, cyclopropanases with high and predictable trans-(1 R,2 R), cis-(1 R,2S), or cis-(1S,2 R)-stereoselectivity in the transformation of a broad range of olefin substrates are designed based on three different hemoprotein scaffolds, including one (indoleamine 2,3-dioxygenase-1) not previously reported to support non-native carbene transfer reactions. Combined with a previously reported trans-(1S,2S)-stereoselective cyclopropanase, this biocatalytic toolbox provides access to a full set of cyclopropane stereoisomers from over 20 structurally diverse olefin substrates with high diastereo- and enantioselectivity (up to 99% de. and 99% ee). Crystal structures of a designed catalyst show good agreement with the computational model and highlight the role of subtle conformational heterogeneity in determining stereoselectivity. We envision that the present computational design methodology can guide the development of biocatalysts with tailored stereoselectivity for other carbene transfer reactions and enzymatic transformations.
PubMed: 41587967
DOI: 10.1038/s41467-026-68327-1
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.1 Å)
Structure validation

248942

건을2026-02-11부터공개중

PDB statisticsPDBj update infoContact PDBjnumon